AML Samples Show High Concordance in Detection of Mutations by NGS at Local Institutions versus Central Laboratories

By sjmartinez • July 18, 2023

Borate U, Yang F, Press RD, Ruppert AS, Jones D, Caruthers S, Zhao W, Vergilio JA, Pavlick D, Juckett L, Norris BA, Bucy T, Burd A, Stein EM, Patel PA, Baer MR, Stock W, Schiller GJ, Blum W, Kovacsovics TJ, Litzow MR, Foran JM, Heerema NA, Rosenberg L, Marcus S, Yocum AO, Stefanos M, Druker BJ, Mims AS. AML Samples Show High Concordance in Detection of Mutations by NGS at Local Institutions versus Central Laboratories. Blood Adv. 2023 Jul 17:bloodadvances.2022009008. doi: 10.1182/bloodadvances.2022009008. Epub ahead of print. PMID: 37459200.

Tags: Hematology/Oncology, Publications

Related Posts

Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results

Hochman MJ, Ruppert AS, Huang Y, Mims A, Borate U, Swords R, Traer E, Baer MR, Duong VH, Stock W, Odenike T, Patel P, Madanat[...]

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

Fakih M, Gill S, Sampat K, Chan DL, Fisher G, Cruz-Correa M, Lenz HJ, Garcia-Alfonso P, Forget F, Lonardi S, Krauss J, Chen E, Cubillo[...]

Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease

Prueksapraopong C, Fernandes A, Campo Fernandez B, Roy S, Hollis RP, Habtemariam B, Pellin D, Ceoldo G, Lin TY, Dang TT, Cornetta K, Romero Z,[...]